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OBJECTIVES: Reduced vitamin E levels have been reported in patients with non-alcoholic steatohepatitis (NASH), but no
conclusive data on patients with simple steatosis (SS) are available. Aim of this study was to investigate the association between
serum vitamin E levels and SS.
METHODS: A cohort of 312 patients with cardio-metabolic risk factors was screened for liver steatosis by ultrasonography (US).
We reasonably classified as SS patients with US-fatty liver, normal liver function tests (LFTs) and with Cytokeratin
18 o246 mIU/ml. Liver biopsy was performed in 41 patients with US-fatty liver and persistent elevation of LFTs (46 months).
Serum cholesterol-adjusted vitamin E (Vit E/chol) levels were measured.
RESULTS: Mean age was 53.9± 12.5 years and 38.4% were women. Non-alcoholic fatty liver disease (NAFLD) was detected at US in
244 patients; of those 39 had biopsy-proven NASH and 2 borderline NASH. Vit E/chol was reduced in both SS (3.4± 2.0, Po0.001),
and NASH (3.5± 2.1, P= 0.006) compared with non-NAFLD patients (4.8± 2.0 μmol/mmol chol). No difference was found between
SS and NASH (P= 0.785). After excluding patients with NASH, a multivariable logistic regression analysis found that
Vit E/chol (odds ratio (OR): 0.716, 95% confidence interval (CI) 0.602–0.851, Po0.001), alanine aminotransferase (ALT, OR: 1.093,
95% CI 1.029–1.161, P= 0.004), body mass index (OR: 1.162, 95% CI 1.055–1.279, P= 0.002) and metabolic syndrome (OR: 5.725,
95% CI 2.247–14.591, Po0.001) were factors independently associated with the presence of SS.
CONCLUSIONS: Reduced vitamin E serum levels are associated with SS, with a similar reduction between patients with SS and
NASH, compared with non-NAFLD patients. Our findings suggest that the potential benefit of vitamin E supplementation should be
investigated also in patients with SS.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most frequent
and emerging liver disease in the general population.1 The
management of NAFLD has become a major clinical
challenge to healthcare practitioners.2 The term NAFLD
includes different liver clinical conditions ranging from simple
steatosis (SS) to non-alcoholic steatohepatitis (NASH),
eventually progressing to cirrhosis and hepatocellular
carcinoma.3 Mechanisms underlying progression from SS to
NASH or cirrhosis remain poorly understood.
Oxidative stress seems to be one of the factors responsible
for the occurrence of liver damage and for the progression to
cirrhosis.4,5 Several markers of oxidative stress have been
measured so far in NAFLD patients with mixed results.6
Particular attention have been focused on vitamin E, which
is an important lipid-soluble vitamin exerting an antioxidant
effect acting as free radical scavenger,7 and protecting cell
membranes and lipoproteins from lipid peroxidation. Vitamin E
is considered a good index of the antioxidant status, as it has
been shown to be inversely correlated with markers of
oxidative stress.8,9
In the context of NAFLD, vitamin E has been found to be
reduced in patients with NASH, and findings from the PIVENS
trial10 suggested that vitamin E supplementation was effective
in improving liver histology in patients with NASH. Never-
theless, the association between vitamin E levels and the
severity of NASH was not confirmed by other studies.6,11–13
One particular aspect of this problem concerns whether a
reduction in the levels of vitamin E may also occur in patients
with SS, i.e., before the onset of NASH. So far, no study has
explored this issue.
The aim of our study was to examine the association
between the serum levels of vitamin E and the presence
of SS in a cohort of patients with cardio-metabolic risk
factors.
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METHODS
The study included 312 consecutive outpatients presenting
with cardio-metabolic risk factors, referring to the Day Service
of Internal Medicine at the Umberto I—University Hospital in
Rome from February 2011 to September 2013. At baseline,
anthropometric data including waist circumference, height
and weight were recorded and body mass index (BMI) was
calculated for each patient. Routine clinical and biochemical
evaluation and ultrasonography (US) examination for liver
steatosis were obtained for all patients.
Inclusion criteria were: US evidence of fatty liver (see
below), no history of current or past excessive alcohol drinking
as defined by an average daily consumption of alcohol420 g;
negative tests for the presence of hepatitis B surface antigen
and antibody to hepatitis C virus. Exclusion criteria were:
presence of cirrhosis and other chronic liver diseases, current
supplementation with antioxidants or vitamins.
Cardiovascular and metabolic risk factors were defined as
follows: arterial hypertension as repeated elevated blood
pressure values (≥140/≥ 90mmHg) or taking antihyper-
tensive drugs;14 diabetes as the presence of symptoms
of diabetes and a casual plasma glucose ≥200mg/dl
(11.1 mmol/l), or fasting plasma glucose ≥ 126mg/dl
(7.0 mmol/l), or presence of anti-diabetic treatment.15 Meta-
bolic syndrome (MetS) was classified according to the
modified criteria of the Adult Treatment Panel III Expert Panel
of the National Cholesterol Education Program.16
All patients provided written informed consent. The study
protocol was approved by the local ethical board of Sapienza
University of Rome and was carried out according to the
principles of the Declaration of Helsinki.17
Blood Collection and laboratory analyses. After overnight,
fasting and supine rest for at least 10min, blood was
withdrawn from the antecubital vein. Serum was divided into
aliquots and stored at −80 °C until assays were performed.
Patients underwent routine laboratory analyses including
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), gamma-glutamyl transpeptidase (GGT), fasting blood
glucose, and lipid profile (total cholesterol, low density
lipoprotein, high-density lipoprotein, and triglycerides).
Vitamin E. Serum levels of vitamin E (α-tocopherol) were
measured by High-Performance Liquid Chromatography.18
Serum samples (100 μl) were supplemented with tocopheryl
acetate (internal standard), deproteinized by the addition
of ethanol, and extracted with hexane. Phase separation
was achieved by centrifugation. The collected upper phase
was evaporated and analyzed using an Agilent 1200 Infinity
series High-Performance Liquid Chromatography system
equipped with an Eclipse Plus C18 column (4.6 × 100mm).
Vitamin E serum levels were expressed as ratio bet-
ween serum α-tocopherol concentration (μmol/l) and
serum total cholesterol concentration (mmol/l) (Vit E/chol,
μmol/mmol), which better expresses the circulating levels of
vitamin E.19
Cytokeratin 18-M30 (CK-18). Serum levels of CK-18 were
measured as marker of liver damage with a commercial
immunoassay (Tema Ricerca, Italy) and expressed as mlU/
ml, as previously reported.5 Intra-assay and inter-assay
coefficients were 6 and 7%, respectively.
Assessment of liver steatosis. We performed liver US to
assess the presence of steatosis. All US were performed by
the same operator who was blinded to laboratory values
using a GE VividS6 (GE Healthcare, Wauwatosa, WI)
apparatus equipped with a convex 3.5 MHz probe. Liver
steatosis was defined according to Hamaguchi criteria based
on the presence of abnormally intense, high-level echoes
arising from the hepatic parenchyma, liver–kidney difference
in echo amplitude, echo penetration into deep portion of the
liver and clarity of liver blood vessel structure.20,21 Steatosis
was assessed semi-quantitatively on a scale of 0–6, defining
4 classes of liver steatosis degree: 0 absent; 1,2 mild; 3,4
moderate; and 5,6 severe.
We reasonably classified as SS patients with US evidence
of liver steatosis and normal liver function tests (LFTs, ALT
≤35 U/L and gamma-glutamyl transpeptidase ≤ 36 U/L) and
with a value of CK-18 o246mIU/ml. This value for the
diagnosis of NASH was taken from a multicentre validation
study previously published by Feldstein et al.22 where the
value of 246mIU/ml showed the best combination of
sensitivity (75%) and specificity (81%).
Liver histology. Percutaneous US-guided liver biopsy was
performed in NAFLD patients with persistent elevation of liver
enzymes (46 months). Liver biopsy was conducted under
conscious sedation using a 16-gauge Klatskin needle. Liver
fragments were fixed in buffered formalin for 2–4 h and
embedded in paraffin with a melting point of 55–57 °C. Three-
to four-lm sections were cut and stained with hematoxylin and
eosin and Masson’s trichrome stains. A single pathologist
blinded to identity, history, and biochemistry of patients
analyzed all the slides. A minimum biopsy specimen length
of 15mm or at least the presence of 10 complete portal tracts
was required. Liver biopsy specimens were classified as to
“definite NASH” (with a NAFLD activity score (NAS) ≥ 5),23
“borderline NASH”24 and “not NASH”.
Statistical analysis. Categorical variables were reported as
counts (percentage); continuous variables were expressed
as mean± s.d. or median and interquartile range. Normal
distribution of parameters was assessed by Kolmogorov–
Smirnov test. Student unpaired t-test and Pearson correlation
analysis were used for normally distributed continuous
variables. Appropriate nonparametric tests (Mann–Whitney
U-test and Spearman rank correlation test) were employed
for all the other variables. Group comparisons were
performed using Fisher’s F-test (Analysis of variance) or
Kruskall–Wallis test when needed.
After excluding patients with NASH, logistic regression
analysis was performed to evaluate the association between
SS and Vit E/chol, and after adjustment for MetS, age, female
gender, smoking, GGT, ALT, AST, statins, and BMI.
Variables were entered with a forced procedure method
(one step) and we used the composite variable of MetS
instead of its single components (which were excluded from
the model).
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All tests were two-tailed and a statistical significance was
set at a P value of o0.05. Analyses were performed using
computer software packages (IBM SPSS Statistics v20.0,
Armonk, NY).
RESULTS
Clinical and biochemical characteristics are listed in Table 1. In
the whole population, mean age was 53.9± 12.5 years and
38.4% were women; 59.2% of patients were affected byMetS.
A diagnosis of US liver steatosis was made in 262 (84.0%) of
the 312 screened patients. Based on CK-18 values, we
excluded 18 patients with US liver steatosis who had normal
LFTs but high values of CK-18 (≥246mIU/ml). Thus, 244
patients with steatosis were used for the analysis. Of these,
22.2% had mild, 41.9% moderate and 35.5% severe
steatosis at US.
In 41 of the 244 NAFLD patients, we observed a persistent
elevation of LFTs. These patients, 22 males and 19 females,
underwent liver biopsy, which revealed in 39 cases the
presence of NASH and in 2 borderline NASH.
A significant difference between patients with and without
SS was observed for BMI, MetS, and diabetes (Table 1). SS
patients had significantly higher mean values of fasting
plasma glucose, and triglycerides, while high-density lipopro-
tein cholesterol values were significantly reduced (Table 1).
Concerning serum markers of liver damage ALT and GGT
were significantly higher in patients with SS compared with
those without (Table 1).
Moreover, a progressive higher value of CK-18 was
detected from patients without fatty liver, to those with SS
and NASH [100.0 (80.0–125.0), 176.0 (145.0–190.0), 266.0
(250.0–284.7) mIU/ml, respectively, Po0.001 NAFLD vs. SS,
Po0.001 SS vs. NASH].
Patients with NASH were younger, less affected by arterial
hypertension, with a higher prevalence of MetS and a
significant elevation of LFTs (Table 1) compared with NAFLD
patients.
Vitamin E levels. To establish normal values of Vit E/chol
we included a control group of 20 healthy subjects (HSs, 13
men and 7 women) from the same geographic area. HSs had
normal weight and no alterations in lipid profile or LFTs and
were not taking any drug or supplement. Differently from the
group of non-NAFLD patients, HSs had no cardio-metabolic
risk factors. Mean value of serum Vit E/chol in HSs was
5.3± 1.5 μmol/mmol (Figure 1). Subjects with SS showed
significantly lower mean values of serum Vit E/chol when
Table 1 Clinical and serological characteristics of patients





Age (years) 55.0±13.5 55.1±12.1 0.996 47.0± 11.5 0.007
Women (%) 36.0 37.4 0.850 46.3 0.392
Smoking (%) 28.0 20.7 0.260 34.1 0.649
Body mass index (kg/m2) 26.7±3.6 31.5±5.7 o0.001 30.0±4.6 0.126
Arterial hypertension (treated) (%) 68.0 65.5 0.868 39.0 0.007
Diabetes (%) 16.0 30.5 0.026 26.8 0.300
Statins (%) 38.0 35.0 0.742 29.3 0.505
Metabolic syndrome (%) 25.0 69.0 o0.001 53.7 0.005
Fasting plasma glucose (mg/dl) 96.7±22.5 109.3±36.2 0.017 101.7±34.7 0.491
Total cholesterol (mg/dl) 202.6±44.0 200.6±39.4 0.749 192.7±34.7 0.693
LDL-c (mg/dl) 123.2±39.4 119.4±34.0 0.478 114.0±30.1 0.628
HDL-c (mg/dl) 55.7±16.8 48.5±13.7 0.010 49.1± 22.4 0.139
Triglycerides (mg/dl) 117.5±66.2 169.9±125.3 0.008 150.0±99.6 0.503
Gamma-glutamyl transpeptidaseb (U/l) 21.0 (14.0–28.0) 23.0 (17.0–34.0) 0.032 52.0 (34.0–138.5) o0.001
Alanine aminotransferase (U/l) 20.0±8.1 26.9±9.4 0.031 78.8± 39.3 o0.001
Aspartate aminotransferase (U/l) 19.5±5.9 21.4±7.8 0.315 47.9± 27.6 o0.001







CK-18, cytokeratin 18; HDL-c, high-density lipoprotein; LDL-c, low density lipoprotein; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
avs. non-NAFLD patients.
bData are expressed as median and interquartile range.
Figure 1 Mean values of vitamin E/cholesterol.
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compared with HSs (Po0.001) and to non-NAFLD patients
(Po0.001) (Figure 1). Similarly, reduced Vit E/chol values
were obtained in the subgroup of 41 NASH/borderline NASH
patients (P= 0.006 vs. NAFLD). No difference was found
between patients with SS and those with NASH/borderline
NASH (P= 0.785). Vit E/chol and CK-18 were inversely
correlated (Rs:−0.185, P= 0.004).
Determinants of simple steatosis. To assess the associa-
tion between SS and Vit E/chol, we performed a multivariable
logistic regression analysis, after excluding the 41 patients
with NASH/borderline NASH. We found that Vit E/chol (odds
ratio (OR): 0.716, Po0.001), ALT (OR: 1.093, P=0.004),
BMI (OR: 1.162, P= 0.002) and MetS (OR: 5.725, Po0.001)
were factors independently associated with the presence of
SS (Table 2).
DISCUSSION
We provide evidence that reduced serum vitamin E levels are
independently associated with the presence of SS in a cohort
of patients with cardio-metabolic risk factors.
Clinical studies so far have analyzed serum vitamin E levels
of patients with NASH in comparison with HSs,6,11–13 and no
data on patients with SS are available.
We reasonably classified as SS patients with presence of
fatty liver at US, normal LFTs and low CK-18 (o246mIU/ml).
Although this classification is not completely accurate, it
reflects common clinical practice, which does not allow to
perform liver biopsy in all patients with US evidence of liver
steatosis and normal liver biomarkers. In fact, liver biopsy
should be considered only for NAFLD patients at increased
risk to haveNASH, andwhowouldmost benefit from histologic
diagnosis to guide therapeutic approach.10 Moreover, in
asymptomatic patients with hepatic steatosis detected on
imaging and normal liver biochemistry, a liver biopsy cannot be
recommended.10
A peculiarity of our study is also in the presence of a
control group of patients with cardio-metabolic risk factors but
without liver steatosis at US. This allows a better analysis of
the association between the presence of NAFLD and the
reduction of vitamin E levels. In fact, NAFLD is strongly
associated with MetS,25,26 and it could be possible
that the reduced Vit E/chol in NAFLD mirrors the coexistence
of MetS.
We found that serum vitamin E levels, along with ALT, BMI,
and MetS, were factors associated with the presence of SS.
The independent association between SS and Vit E/chol
suggests that other mechanisms than MetS may account
for the inverse association between liver steatosis and
Vit E/chol.
An interesting finding of our study is the similar reduction of
Vit E/chol levels in patients with SS and in those with biopsy-
proven NASH, compared with NAFLD patients.
This comparable reduction of vitamin E is intriguing, but of
difficult pathophysiologic explanation, given the difference in
the natural history of SS and NASH. Our findings suggest that
patients with NAFLD may have an early enhanced systemic
oxidative stress, which leads to a reduction in natural
antioxidant pool, including vitamin E. However, in the present
study we cannot establish whether the imbalance of the
oxidant status may directly contribute to the progression from
SS to NASH.
Moreover, differently from previous studies, we expressed
values of vitamin E after adjustment for total serum choles-
terol. This is important, since the plasma concentration of fat-
soluble vitamins, such as vitamin E, varies with the amount of
plasmatic lipids, and thus requires lipid standardization,
especially in conditions likely to raise serum cholesterol.19
The high percentage of NASH at liver biopsy is only partially
surprising. In fact, the reported rate of biopsy-proven NASH is
highly variable, and can reach 40% in unselected patients
without known liver disease, as reported in a Greek study on
600 autopsies.1 In our study, patients who underwent liver
biopsy had all persistent elevation of LFTs for at least
6 months, and more than 50% suffered from MetS with a
mean BMI of 30 kg/m2; all these conditions are strictly
associated with the presence of NASH.27,28 This finding
supports the high prevalence of NASH in high-risk patients
with cardio-metabolic disorders.
Our study has a number of limitations. We detected fatty
liver by US, a qualitative method, inadequate to quantify
o30% liver fat content. Nevertheless, US is safe and
inexpensive and uses standardized criteria to define liver
steatosis.21 Moreover, the separation of SS from NASH is
difficult with non-invasivemethods, and the presence of NASH
is underestimated given the possibility to perform liver biopsy
only in patients with persistent abnormalities in LFTs. Serum
CK-18 levels were measured to reduce this potential
classification bias. However, even if the cutoff of CK-18 used
in our study for the discrimination of patients with SS from
those with NASH derives from a multicentre study, it is not
currently recommended for the non-invasive diagnosis
of NASH.
The study may have some implications. Considering that
low levels of vitamin E are associated with increased
cardiovascular risk,29–32 our findings may further support the
role of NAFLD as cardiovascular risk factor. In this context,
statins could be a promising therapeutic approach, as they
increase serum vitamin E,8,33,34 and improve liver steatosis.35
In conclusion, we found that patients with SS and those with
biopsy-proven NASH have a similar reduction of serum levels
of Vit E/chol compared with non-NAFLD patients, suggesting
Table 2 Multiple logistic regression analysis of determinants of simple
steatosis
OR 95% CI P value
Vitamin E/cholesterol 0.716 0.602 0.851 o0.001
Statins 0.721 0.297 1.752 0.471
Smoking 0.651 0.255 1.664 0.370
Age 0.978 0.944 1.012 0.203
Female 0.955 0.401 2.275 0.917
Body mass index 1.162 1.055 1.279 0.002
Aspartate aminotransferase 1.001 0.938 1.068 0.985
Alanine aminotransferase 1.093 1.029 1.161 0.004
Gamma-glutamyl transpeptidase 0.995 0.975 1.016 0.654
Metabolic syndrome 5.725 2.247 14.591 o0.001
Constant 0.058 0.123
CI, confidence interval; OR, odds ratio.
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that oxidative stress imbalance could occur in the early stages
of fatty liver disease.
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Study Highlights
WHAT IS CURRENT KNOWNLEDGE
✓ Vitamin E serum levels are reduced in patients with biopsy-
proven NASH.
✓ Vitamin E supplementation is currently recommended for
non-diabetic patients with NASH.
WHAT IS NEW HERE
✓ This is the first report on the association between reduced
serum Vitamin E levels and the presence of simple
steatosis.
✓ Patients with simple steatosis and NASH showed a similar
reduction of serum cholesterol-adjusted levels of Vitamin E.
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